M&A Deal Summary |
|
|---|---|
| Date | 2022-05-02 |
| Target | Nevakar Injectables - Six Development-Stage Product |
| Sector | Life Science |
| Buyer(s) | Endo International |
| Sellers(s) | Nevakar Injectables |
| Deal Type | Divestiture |
| Deal Value | 35M USD |
SEARCH BY
| Category | Company |
|---|---|
| Founded | 1920 |
| Sector | Medical Products |
| Employees | 3,103 |
| Revenue | 2.9B USD (2020) |
Endo International is a pharmaceutical company engaged in the research, development, sale and marketing of branded and generic prescription pharmaceuticals used to treat and manage pain, bladder cancer, prostate cancer and the early onset of puberty in children, or central precocious puberty (CPP). Endo International was incorporatted in 1920 and is based in Dublin, Ireland.
| DEAL STATS | # |
|---|---|
| Overall | 16 of 16 |
| Sector: Life Science M&A | 11 of 11 |
| Type: Divestiture M&A Deals | 1 of 1 |
| State: New Jersey M&A | 3 of 3 |
| Country: United States M&A | 14 of 14 |
| Year: 2022 M&A | 1 of 1 |
| Size (of disclosed) | 13 of 14 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2020-10-19 |
BioSpecifics Technologies
Wilmington, Delaware, United States BioSpecifics Technologies Corp. is a commercial-stage biopharmaceutical company that discovers and develops a proprietary form of injectable collagenase (CCH), which is currently marketed by Endo, as XIAFLEX in North America for the treatment of Dupuytren's contracture and Peyronie's disease. Endo announced that it received FDA approval of CCH for the treatment of moderate to severe cellulite in the buttocks of adult women; Qwo is expected to be available commercially in the U.S. starting in the first half of 2021. The CCH research and development pipeline includes several additional potential indications including adhesive capsulitis and plantar fibromatosis. |
Buy | $540M |
| Category | Company |
|---|---|
| Founded | 2015 |
| Sector | Life Science |
Nevakar Injectables is a biopharmaceutical company with an extensive portfolio of products in the ophthalmic and injectable areas. Nevakar Injectables is developing a broad portfolio of injectable products for use in the hospital and ambulatory care settings. Nevakar Injectables was founded in 2015 and is based in Bridgewater, New Jersey.
| DEAL STATS | # |
|---|---|
| Overall | 1 of 1 |
| Sector: Life Science M&A | 1 of 1 |
| Type: Divestiture M&A Deals | 1 of 1 |
| State: New Jersey M&A | 1 of 1 |
| Country: United States M&A | 1 of 1 |
| Year: 2022 M&A | 1 of 1 |
| Size (of disclosed) | 1 of 1 |
